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ABSTRACT
The prevalence of global obesity is increasing. Obesity is associated with general 
cancer-related morbidity and mortality and is a known risk factor for development 
of specific cancers. A recent large systematic review of 24 studies based on meta-
analysis of 11,149 patients with prostate cancer showed a significant correlation 
between obesity and the risk of advanced prostate cancer. Further, a sustained 
reduction in BMI correlates with a decreased risk of developing aggressive disease. 
On the other hand, the correlation between consuming different products and prostate 
cancer occurrence/risk is limited. 
Here, we review the role of adipose tissue from an endocrine perspective and 
outline the effect of adipokines on cancer metabolism, with particular focus on 
leptin. Leptin exerts its physiological and pathological effects through modification 
of intracellular signalling, most notably activating the Janus kinase (JAK) 2/signal 
transducer and activator of transcription (STAT) 3 pathway and recently shown 
sphingolipid pathway. Both high levels of leptin in circulation and leptin receptor 
mutation are associated with prostate cancer risk in human patients; however, the 
in vivo mechanistic evidence is less conclusive. 
Given the complexity of metabolic cancer pathways, it is possible that leptin may 
have varying effects on prostate cancer at different stages of its development, a point 
that may be addressed by further epidemiological studies.
OBESITY AND CANCER
There is currently a global epidemic of obesity. 
Overall, 33% of the world’s adult population are 
overweight or obese, according to a survey conducted in 
2005 [1]. If this trend continues, by 2030 this figure will 
have doubled. Epidemiological studies highlight obesity 
and its associated complications as a major health problem 
[2]. 
Obesity is a recognised risk factor for diabetes, 
arteriosclerosis, ischaemic heart disease and hypertension. 
Further, epidemiological studies have shown that obesity 
is associated with a multitude of cancer types including 
colorectal, hepatic, oesophageal, pancreatic, endometrial, 
ovarian and post-menopausal breast cancer [3-5]. Obese 
cancer patients have a higher death rate in comparison 
to their non-obese counterparts, with the increased death 
rate presenting for all cancers combined, regardless of 
whether obesity was a risk factor in the development of 
the specific cancer [3]. The pathophysiology of obesity-
associated cancer varies with cancer type. Recognised 
mechanisms include chronic elevated insulin levels and 
insulin resistance, persistent local inflammation and higher 
secretion of steroid hormones (reviewed in [2]).
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At present, there are reports of a robust empirical 
correlation between obesity and several types of cancer 
[3-5]. Due to the relative ease of obtaining patients’ height 
and weight, especially important when conducting large-
scale studies, in the vast majority of previous studies, 
obesity has been measured using body mass index (BMI), 
defined as the weight (kilograms) divided by the square of 
the height (meters). The epidemiologic evidence links an 
increased BMI to an increased propensity to oesophageal 
adenocarcinoma, thyroid, kidney, and colon cancer 
among men whereas strong correlations between BMI 
and endometrial, gallbladder, kidney, and oesophageal 
cancer have been established in women [6]. In both 
sexes increased BMI was associated with decreased 
survival of patients with cancer of the oesophagus, colon, 
liver, gallbladder, pancreas, and kidney, as well as non-
Hodgkin’s lymphoma and multiple myeloma [3, 5]. 
OBESITY AND PROSTATE CANCER: 
CLINICAL EVIDENCE
Historically, there is a considerable amount of 
available data indicating a lack of association between 
prostate cancer incidence and high BMI (Table 1) [7, 
8]. A large prospective study of BMI/weight change in 
relation to prostate cancer incidence and mortality found 
no correlation between prostate cancer incidence and 
an individual’s high BMI. Nevertheless, higher BMI/
weight gain is correlated with increased propensity to die 
from prostate cancer [8]. This apparent controversy may 
potentially be explained by the fact that testosterone (often 
suppressed in men with high BMI) is required for prostate 
tissue proliferation and therefore an inverse association 
between BMI and indolent prostate cancer is observed. On 
the other hand, a recent study has shown that testosterone 
helps maintain prostatic epithelium differentiation [9] 
indicating that low testosterone may increase the risk of 
developing poorly differentiated and hormone-insensitive 
prostate tumours. A recent report confirmed these findings 
of increased aggressiveness and mortality (but not prostate 
cancer incidence) in men with higher weight and BMI [7]. 
Further, obesity is associated with higher rate of Prostate 
specific antigen recurrence following external-beam 
radiotherapy or radical prostatectomy [10]. A biopsy 
cohort analysis showed that obesity was associated with 
a high-grade Gleason score on diagnosis of prostate 
cancer despite raised BMI not being a significant risk 
for developing prostate cancer [11]. Both BMI and waist 
circumference are predictors of high-grade prostate cancer, 
however obesity with central adiposity was shown to be 
the strongest predictor of diagnosing prostate cancer 
and high-grade disease [12]. A recent large trial of 2235 
biopsy patients in Canada investigating the influence of 
the metabolic syndrome (any three of five components: 
obesity, elevated blood pressure, diabetes or impaired 
fasting glucose, low high-density lipoprotein-cholesterol, 
and hypertriglyceridemia) on Prostate cancer has shown 
that while no individual metabolic syndrome component 
was independently associated with Prostate cancer, overall 
metabolic syndrome was associated with higher Prostate 
cancer grade (p<0.001), as well as progressively higher 
odds of Prostate cancer outcomes: clinically significant 
prostate cancer and intermediate or high grade prostate 
cancer [13]. A recent study has shown that the presence 
of metabolic syndrome is a significant risk factor for 
shorter progression free survival in CRPC patients treated 
with abiraterone [14]. The association between obesity 
and aggressive prostate cancer is stronger in Caucasian 
Americans as opposed to African Americans; however, the 
latter tend to have more aggressive disease independent of 
obesity [15]. 
With respect to decreased incidence of prostate 
cancer in relation to weight loss, men who maintained 
weight loss of greater than 11 pounds over a 10-year 
period had a decreased risk of non-metastatic high-grade 
prostate cancer. However, while high BMI was positively 
associated with non-metastatic high-grade prostate 
cancer it was simultaneously inversely associated with 
the risk of developing low-grade disease [16]. This may 
suggest that in contrast to low-grade prostate cancer, the 
pathogenesis of high-grade disease may be intrinsically 
linked to obesity-driven signalling. Indeed, meta-analysis 
of 16 published studies of 6569 cases and 8405 controls 
for the leptin receptor G2548A mutation showed that it 
is statistically significantly associated with an increased 
risk of prostate cancer (OR=1.26, 95% CI=1.05-1.51) 
[17]. Furthermore, men with high-volume prostate cancer 
(greater than 0.5cc in volume or extraprostatic disease) 
had higher serum leptin concentrations than their low 
volume counterparts when stratified by age, testosterone 
level, height and BMI [18].
In contrast to BMI, in a cohort study of 8152 men 
followed up for 15 years dietary carbohydrates (cake, 
biscuits, rice and pasta) have been associated with 
developing a low-grade prostate cancer, but not with 
high-grade disease [19]. A study on fatty acid intake in 
relation to prostate cancer risk identified an increased risk 
of advanced prostate cancer with increased dietary intake 
of α-linolenic acid, but it was not associated with risk 
of total prostate cancer [20]. However in a recent large 
systematic review and meta-analysis of 11,149 patients 
with prostate cancer the correlation between consuming 
different products and prostate cancer occurrence/risk 
was limited and inconclusive [21]. A recent single centre 
study showed that increased physical activity is associated 
with a reduced risk of prostate cancer and of high-grade 
prostate cancer on biopsy [22]. 
OBESITY AND PROSTATE CANCER: 
CELL AND ANIMAL MODELS
Tumour growth in immunodeficient mice injected 
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with prostate cancer LAPC-4 xenografts was slower in 
mice on low-fat diets as opposed to their high-fat diet 
counterparts [23]. Several proteins secreted by adipocytes 
play a role in prostate cancer progression. The expression 
of leptin receptor (LEPR) in prostate cancer influences 
the extent of tumour differentiation with no remarkable 
correlation between leptin levels in tumour tissues and 
BMI [24] or between circulating plasma leptin levels 
and BMI [25]. Collectively, the available evidence 
suggests that although it is unlikely for obesity to affect 
incidence of prostate cancer per se, obesity may affect 
the progression of existing prostate cancers. A role of 
adipokines in the aggressiveness of prostate cancer in 
obese males has been proposed [26]. This hypothesis states 
that cancerous prostate cells from obese individuals have 
a disrupted metabolic status, as they are being exposed 
to elevated levels of adipokines (e.g. leptin, interleukin 
(IL)-6 and vascular endothelial growth factor (VEGF), 
either via the circulation or in a localised manner upon the 
invasion of a retropubic fat pad. As a consequence of the 
abundance of obesity-related molecules, prostate cancer 
cell proliferation, differentiation, and angiogenesis can 
be promoted, worsening the pathophysiological outcome 
[26]. In addition to adipokines, excess body fat leads to 
altered serum levels of hormones, such as testosterone and 
insulin, which also might play a role in prostate cancer 
progression [27]. Murine prostate cancer cells exposed in 
vitro to obese sera had upregulated vimentin, β-catenin, 
e-cadherin dispersion and matrix metalloproteinase-9 
which correlates with increased cellular invasion and 
migration. This may be a plausible mechanism in 
human cancer cells that correlates to prostate cancer 
aggressiveness [28]. There are recent reports showing a 
novel mechanisms of leptin signalling, linking it to the 
sphingolipid signalling [29, 30]. Sphingosine kinase 1 was 
shown to be highly active in human prostate tumours [31] 
and linked with prostate cancer chemoresistance [32-37].
OBESITY AND ADIPOKINES
Obesity is defined by excessive growth of adipose 
tissue [2]. Two distinct types of adipose tissue have been 
identified: white adipose tissue (WAT) and brown adipose 
tissue (BAT). WAT constitutes the vast majority of the 
body’s adipose tissue and functions as a storage site for 
excess fat in the form of lipid. On the other hand, BAT 
exists mostly in human neonates and regulates energy 
expenditure by adaptive thermogenesis. In addition to 
its storage role, the excessive growth of adipose tissue is 
detrimental to many physiological processes. Thus, the 
current paradigm of adipose tissue physiology has been 
revised based on its ability to act as an extremely active 
endocrine organ. In this context, WAT responds to and 
emanates bioactive substances that regulate biological 
processes like energy homeostasis, immunity and 
endocrine functions [38]. 
More than fifty adipose-derived factors, collectively 
termed adipokines, have been identified. Adipokines are 
proteins produced mainly by adipocytes, which comprise 
the majority of WAT. These secreted proteins comprise 
cytokines (e.g. tumour necrosis factor (TNF)-α and IL-6), 
angiogenic factors (e.g. VEGF and apelin) as well as other 
factors produced mainly by adipocytes (e.g. leptin and 
adiponectin) [38]. In addition, different parts of the body 
have distinctive adipokine profiles, rendering adipokines 
even more heterogeneous with respect to location. Overall, 
adipocytes have an extensive communication network of 
autocrine-paracrine signals with other tissues and organs, 
which has a significant impact on tissue homeostasis.
LEPTIN SIGNALLING AND ITS 
PHYSIOLOGICAL ROLE
The discovery of leptin in 1994 shed light on one 
of the most important adipose tissue derived factors [39]. 
Leptin (from the Greek leptos meaning thin) is a versatile 
16 kDa polypeptide encoded by the obese (Ob) gene (LEP 
gene by HUGO nomenclature) [39]. Leptin is mainly 
produced in adipose tissues, but is also synthesised in 
other, non-adipose tissue sites like the stomach, skeletal 
muscles and mammary epithelium.
Leptin acts as a circulating hormone to regulate 
appetite and the expenditure of energy via its action on 
specific receptors expressed in the hypothalamus [40]. 
The levels of leptin in plasma are proportional to fat 
mass and increase as body weight rises [40]. In humans, 
leptin circulates as a free hormone or bound to a soluble 
LEPR. The ratio of bound/free leptin varies between 
Table 1: Association of BMI with prostate cancer incidence.
Study Year Sample Size OR/HR/RR
Wright et al. 2007 287,760 RR 0.67
Su et al. 2011 1132 OR 1.48
Bassett et al. 2012 17,045 HR 1.06
De Nunzio et al. 2013 668 OR 1.05
This table highlights key articles that studied the association between a high baseline body mass index (BMI) and 
risk of subsequently developing prostate cancer. The association is expressed as an odds ratio (OR), hazard ratio 
(HR)  or relative risk (RR). Su et al., studied the association of BMI with aggressive prostate cancer. Adapted from 
(Bassett et al., 2011; Su et al., 2011;De Nunzio et al., 2013; Wright et al., 2007)
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high levels in lean individuals, with low amounts of 
adipose tissue, and low levels in obese subjects, where 
the majority of leptin available is in its free form [41]. 
Additional pleiotropic effects of leptin include modulation 
of immune responses, angiogenesis, neovascularization 
and bone formation [42]. LEPR was first cloned from 
a mouse choroid plexus cDNA library [43]. LEPRs are 
products of a single LEPR gene. Further analysis of both 
human and mouse LEPR revealed the presence of multiple 
isoforms, including a form with a longer intracellular 
domain comprising approximately 306 amino acid (shorter 
in mice than in humans) hosting motifs, suggestive of 
intracellular signalling potential. Indeed, LEPR has 
structural similarities to members of the class-I cytokine 
receptor family. It shares highest sequence similarity with 
glycoprotein 130 (gp130) (a signal transducing component 
of IL-6 receptor), leukaemia inhibitory factor, oncostatin 
receptors, and with the receptor for granulocyte colony-
stimulating factor. Therefore, LEPR possesses no intrinsic 
tyrosine kinase activity and initial signalling events are 
dependent on association with kinases like Janus kinase 
(JAK)2 [44].
The extracellular domain of LEPR is similar among 
the different isoforms due to the fact that differences in 
receptor isoforms arise from alternative RNA splicing 
at the C-terminus, resulting in different sequences and 
lengths of the intracellular domains. Six different isoforms 
of LEPR have been identified in mice [44] while four 
have been identified in humans. In all species, LEPR 
can be divided into three classes: long, short and soluble 
isoforms.
Both long and short isoforms of LEPR exist in 
dimeric form, even in the absence of leptin, and are 
activated upon leptin binding to the extracellular domain 
of LEPR in a 1:1 ratio. Dimerisation is pivotal for receptor 
activation and a prerequisite for execution of downstream 
signalling [45]. All isoforms (except the soluble isoform) 
share an identical intracellular domain, which associates 
with JAK, critical for JAK2 activation. The longest 
isoform of LEPR also contains a Box2 binding site and 
signal transducer and activator of transcription (STAT) 
binding sites [46]. The shortest isoform is soluble 
and is not involved in leptin signalling, as both the 
transmembrane and cytoplasmic domains are absent. 
Figure 1: Role of LEPR-Long phosphorylation in leptin signalling. LEPR-Long contains tyrosine residues (Tyr 974, Tyr 986, 
Tyr1077 and Tyr 1138). Tyr 1138 recruits STAT3 while Tyr 1138 and Tyr 1077 recruit STAT5. Phosphorylation at Tyr 986 and on Tyr 
974 leads to SHP2 binding. JAK2 auto-phosphorylation at the Box1 motif leads to phosphorylation of IRS1/2, which can activate PI3K/
Akt pathway. SFKs are also activated by leptin. Akt, protein kinase B; JAK2, Janus kinase 2; IRS1/2, insulin receptor substrate 1/2; 
GRB2, growth factor receptor-bound protein 2; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3 kinase; SHP2, SH2 
domain-containing tyrosine phosphatase 2; STAT3, signal transducer and activator of transcription 3.
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However, it can act as a leptin-binding protein to regulate 
the circulating levels of free leptin [41].
LEPR-Long hosts three conserved tyrosine residues 
linked to activation of distinct downstream signalling 
pathways (Tyr 986, Tyr 1077 and Tyr 1138) (Figure 1). 
Importantly, Tyr 1138 becomes phosphorylated following 
leptin binding. As a consequence, recruited STAT3, via its 
Src homology (SH)2 domain, becomes activated, followed 
by homodimerisation and nuclear translocation [47]. Tyr 
1077 and Tyr 1138 can activate other STAT isoforms in 
addition to STAT3. Both Tyr 1077 and Tyr 1138 bind 
STAT5 whereas Tyr 1138 recruits STAT1. 
Activation of Tyr 985 is required for triggering rat 
sarcoma (Ras)/rapidly accelerated fibrosarcoma (Raf)/ 
extracellular signal-regulated kinases 1/2 (ERK1/2) 
pathways through interaction with an adaptor protein, 
growth factor receptor-bound protein 2 (GRB2) [47]. 
Phosphorylation at Tyr 986 (Tyr 985 in rodents) and Tyr 
974 leads to SH2 domain-containing tyrosine phosphatase 
2 (SHP2), also called protein tyrosine phosphatase, non-
receptor type 11 (PTPN11) binding to these residues [48]. 
While binding of SHP2 to Tyr 986 leads to its activation it 
has been proposed that this is followed by SHP2-mediated 
dephosphorylation of Tyr 974, suggesting the ability of 
SHP2 to down-regulate activity of proteins binding at 
this site [48]. LEPR lacking Tyr 985 induces activation 
of ERK, although at a reduced rate, and this is due to 
an alternative ERK1/2 activation pathway, independent 
of receptor phosphorylation, via interaction of SHP2 
and GRB2 with JAK2 [49]. JAK2 auto-phosphorylation 
at the Box1 motif leads to phosphorylation of insulin 
receptor substrate 1/2 (IRS1/2) which can activate the 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway [47] 
(Figure 1). 
Intriguingly, leptin retains the ability to stimulate 
STAT3 and ERK1/2 in cultured cells genetically deficient 
in JAK2 [50]. These JAK2-independent responses appear 
to be mediated by members of the Src family kinases 
(SFKs). Kinase inactive JAK2 introduced in JAK2-
deficient cells enhances leptin signalling, suggesting 
that JAK2, besides its tyrosine kinase activity, can act 
as an adaptor to transduce leptin signals [50]. However, 
JAK2-dependent and-independent pathways seem to act 
cooperatively to mediate leptin responses [50].
Activation of STAT3 upon leptin binding also leads 
to activation of the negative feedback regulator suppressor 
of cytokine signalling 3 (SOCS3), which in turn attenuates 
leptin signalling by binding Tyr 985 and preventing JAK2 
activation [51]. Resistance to leptin action is believed to 
be mediated through SOCS3 since in vitro overexpression 
of this protein blocked leptin-mediated signalling. In 
addition, another negative regulator of leptin signalling, 
and a possible contributor to its resistance, is protein 
tyrosine phosphatase 1B (PTP1B), a class 1 nonreceptor 
PTP. PTP1B is capable of inhibiting leptin signalling by 
dephosphorylating JAK2 [52].
MOLECULAR EFFECTS OF LEPTIN ON 
PROSTATE CANCER
Long-term exposure to leptin was shown to 
enhance the growth of all three main prostate cancer cell 
lines (LNCaP, DU145 and PC-3) [53], where androgen-
insensitive prostate cancer cell lines DU145 and PC-3 
show a stronger proliferative response to leptin treatment 
in comparison to androgen-sensitive LNCaP cells [54]. 
Leptin also induces the expression of VEGF, transforming 
growth factor β1, and basic fibroblast growth factor in 
DU145 and PC-3 cells, stimulating cell survival pathways 
and leading to proliferation and angiogenesis [55], 
although these results have not been reproduced in another 
study [56]. Another mechanism of leptin-induced prostate 
cell proliferation was suggested in a recent study showing 
that leptin influences estrogen metabolism and causes an 
increase in the expression of estrogen receptor (ER)-α 
and a decrease in ER-β [57]. Leptin was shown to induce 
cellular migration of human prostate cancer mediated 
via upregulation of αvβ3 integrin and intracellular signal 
transduction [58]. 
In vivo, low-leptin ob/ob mice injected with 
murine androgen-insensitive prostate cancer cell line 
RM-1, developed larger tumours and had stronger Ki-
67 staining than high-leptin db/db mice [59]. However, 
epidemiological evidence supports leptin influence on the 
promotion of prostate cancer [24] and developing larger 
tumours [18]. Leptin receptor mutation is significantly 
associated with an increased risk of prostate cancer [17]. 
Of note, new leptin receptor antagonists are currently 
becoming available for therapeutic targeting of obesity-
associated pathways (reviewed in [60]). They already have 
been shown to inhibit in vitro and in vivo growth of breast 
cancer [61] and melanoma cells [62].
CONCLUSIONS
It is now clearly established that obese patients with 
prostate cancer tend to have more aggressive disease, while 
there is still conflicting evidence regarding the association 
of obesity and risk of developing prostate cancer. Overall, 
the available evidence suggests that although it is unlikely 
for obesity to affect incidence of prostate cancer per se, 
obesity may affect the progression of existing prostate 
cancers, specifically the high-grade ones. The exact 
mechanism of this effect is unknown, and hypotheses 
range from the alteration in the testosterone effect on 
indolent vs high-grade tumours, to a multifactorial 
influence of adipose tissue secreted factors. Indeed, 
expression of multiple cytokine receptors including IL-6 
and TNF-α is increased in prostate cancer in comparison 
to control tissue [63], and rises with Gleason grade [64]. 
Leptin is a prominent adipokine secreted by adipose tissue 
that has been linked to progression and metastasis of many 
cancers. Similarly to obesity, leptin was shown to correlate 
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with increased prostate cancer risk and developing of 
larger tumours, while the data linking leptin levels with 
prostate cancer incidence is inconclusive. It is possible 
that obesity and leptin affect only specific types of prostate 
cancers or only certain events during tumour progression 
such as epithelial/mesenchymal transition, metastasis or 
angiogenesis. Therefore, further epidemiological studies 
should be combined with histopathological studies 
analysing adipokine and adipokine receptor expression 
in an attempt to classify different subtypes of prostate 
cancer that may be more prone to obesity-related changes. 
These could be further facilitated using metabolomics and 
systems biology approaches and such data could yield 
stronger associative evidence. 
In a view of recent findings linking leptin signalling 
to the sphingolipid pathway it may be reasonable to 
investigate this link in prostate cancer, specifically in a 
view of developing new chemo- or radio-sensitizing 
therapies. This is particularly timely, as new leptin 
receptor antagonists are currently becoming available for 
therapeutic targeting. If there is a rationale for their use in 
prostate cancer, clear patient subsets need to be identified. 
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